Co-targeting CDK4/6 enhances anti-cancer activity and alleviates immune-related adverse events of anti-PD-1 antibody for breast cancer.
Hu SW, Yeh MH, He YH, Wei YL, Cheng FJ, Yeh YL, Huynh TK, Liu PT, Hu DW, Chang TH, Wang BW, Chen BR, Lin MC, Lee DY, Hsieh YH, Hsu YM, Tang CH, Ho PC, Hung MC, Huang WC.
Hu SW, et al. Among authors: lin mc.
Cell Rep Med. 2025 Oct 30:102429. doi: 10.1016/j.xcrm.2025.102429. Online ahead of print.
Cell Rep Med. 2025.
PMID: 41172995